



Mouse Anti-Mouse CD45.2 Monoclonal antibody, clone 104.2 (CABT-L4528)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	The 104.2 monoclonal antibody reacts with mouse CD45.2
Target	Mouse CD45.2
Immunogen	B10.S mouse thymocytes and splenocytes
Isotype	IgG2a, κ
Source/Host	Mouse
Species Reactivity	Mouse
Clone	104.2
Purification	Protein G purified. Purity>95%. Determined by SDS-PAGE
Conjugate	Functional Grade
Applications	FC, in vivo CD45.2 blockade, in vitro CD45.2 blockade, IHC-F
Molecular Weight	150 kDa
Format	0.2 µm filtration liquid. Purified from tissue culture supernatant in an animal free facility
Concentration	Lot specific
Size	5 mg
Buffer	PBS, pH 7.0. Contains no stabilizers or preservatives. [low endotoxin azide-free]

Endotoxin level: <2EU/mg (<0.002EU/μg). Determined by LAL gel clotting assay
Related dilution buffer: CABT-LB04

Preservative	None
---------------------	------

Storage	The antibody solution should be stored undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze.
----------------	---

Ship	Wet ice
-------------	---------

BACKGROUND

Introduction	The 104.2 monoclonal antibody reacts with mouse CD45.2 a 180-240 kDa member of the protein tyrosine phosphatase family. CD45.2 is an alloantigen of CD45 and is only expressed by certain mouse strains including C57BL/6, CBA, 129, A, AKR, C58, DBA/1, DBA/2, BALB/c, and C3H/He. The 104.2 monoclonal antibody does not react with leukocytes of CD45.1-expressing mouse strains including DA, SJL/J, RIII, and STS/A. CD45.2 is expressed on all hematopoietic cells except mature erythrocytes and platelets and is thought to be involved in TCR and BCR signal transduction. The 104.2 antibody has been shown to block B cell responses in vitro and reduce serum autoantibody concentration in vivo in SLE-prone mice.
---------------------	---

Keywords	CD45;CD45.2;
-----------------	--------------

GENE INFORMATION

References	Utzschneider, D. T., et al. (2013). "T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion." Nat Immunol 14(6): 603-610. PubMed;
-------------------	--
